Acrobat Genomics Awarded NIH Grant to Advance Gene Editing Technology for Neurodegenerative Diseases
October 09, 2024
We are thrilled to announce that Acrobat Genomics has been awarded an SBIR grant from the National Institute on Aging (NIA) at the NIH. This grant is a significant milestone in our mission to develop next-generation gene editing tools that can provide transformative treatments for genetic diseases, particularly neurodegenerative conditions.
What This Means for Genetic Medicine
Neurodegenerative diseases are driven by mutations in a diverse set of key genes that have been extensively studied through decades of basic and biomedical research. In spite of this extensive knowledge, current therapeutic options are limited, often treating symptoms rather than addressing the root cause. At Acrobat Genomics, we’re pioneering a new approach to target the underlying genetic errors that drive neurodegeneration.
This NIH grant will enable us to take critical steps forward by:
Enhancing our gene editing technology through advanced computationally guided high-throughput screening to increase precision and efficacy.
Focusing on neurodegenerative diseases, starting with ALS and FTD, which present complex challenges but offer the potential for breakthrough treatments.
Accelerating research and development of a gene editor that can be directly delivered to the patient without the need for potentially invasive and costly procedures.
How the Grant Supports Our Mission
This grant not only validates the potential of our technology but also provides crucial funding to expand our research capabilities. We’ll use this support to enhance our high-throughput screening capabilities and optimize our novel gene editor for in vivo delivery, moving closer to clinical trials. By combining advanced computational methods with a tailored screening process, we aim to develop therapeutic options that are more effective than current treatments.
Looking Ahead
In the coming months, we will share updates as we achieve critical milestones, including further data on the precision and safety of our gene editing platform. With the support of the NIH and our broader network of advisors, investors, and collaborators, Acrobat Genomics is poised to make significant strides in the fight against genetic diseases.
Thank You to Our Supporters
We want to extend our gratitude to the NIH, our dedicated team, and our investors who believe in our mission to create innovative solutions for some of the most challenging diseases. This grant is a testament to the hard work and vision of everyone involved, and we are excited about what lies ahead.
